James E Flynn Insider Trading $ALIM ALIMERA SCIENCES INC
Get free email notifications about insider trading for James E Flynn.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of James E Flynn. James E Flynn is 10% Owner in CAS MEDICAL SYSTEMS INC ($CAMY.OB) and 10% Owner in AxoGen, Inc. ($LECT) and 10% Owner in PAR PHARMACEUTICAL COMPANIES, INC. ($PRX) and 10% Owner in Fibrocell Science, Inc. ($FCSC) and 10% Owner in STREAMLINE HEALTH SOLUTIONS INC. ($LANV) and 10% Owner in ANTARES PHARMA, INC. ($ATRS) and 10% Owner in VIA Pharmaceuticals, Inc. ($CAQ) and 10% Owner in DUSA PHARMACEUTICALS INC ($DUSA) and 10% Owner in HI TECH PHARMACAL CO INC ($HITK) and 10% Owner in AVADEL PHARMACEUTICALS PLC ($AVDL) and 10% Owner in INSPIRE PHARMACEUTICALS INC ($ISPH) and 10% Owner in RIGEL PHARMACEUTICALS INC ($RIGL) and 10% Owner in ARENA PHARMACEUTICALS INC ($ARNA) and 10% Owner in ISTA PHARMACEUTICALS INC ($ISTA) and 10% Owner in MEDICINES CO /DE ($MDCO) and 10% Owner in THIRD WAVE TECHNOLOGIES INC /WI ($TWTI) and 10% Owner in DYNAVAX TECHNOLOGIES CORP ($DVAX) and 10% Owner in Cyclacel Pharmaceuticals, Inc. ($CYCC) and Director in Talon Therapeutics, Inc. ($EMLR) and 10% Owner in LUMOS PHARMA, INC. ($NLNK) and 10% Owner in NITROMED INC ($NTMD) and 10% Owner in XENOPORT INC ($XNPT) and 10% Owner in EMAGEON INC ($EMAG) and 10% Owner in CATALYST BIOSCIENCES, INC. ($CBIO) and 10% Owner in ALIMERA SCIENCES INC ($ALIM) and 10% Owner in NeuroMetrix, Inc. ($NURO) and 10% Owner in NxStage Medical, Inc. ($NXTM) and 10% Owner in aTYR PHARMA INC ($LIFE) and 10% Owner in Vanda Pharmaceuticals Inc. ($VNDA) and 10% Owner in XERIS PHARMACEUTICALS INC ($XERS) and Director in PROTEON THERAPEUTICS INC ($PRTO) and 10% Owner in eHealth, Inc. ($EHTH) and 10% Owner in ZAFGEN, INC. ($ZFGN) and 10% Owner in NeurogesX Inc ($NGSX) and 10% Owner in Invuity, Inc. ($IVTY) and 10% Owner in Dicerna Pharmaceuticals Inc ($DRNA) and 10% Owner in CONSTELLATION PHARMACEUTICALS INC ($CNST) and 10% Owner in TriVascular Technologies, Inc. ($TRIV) and 10% Owner in Auspex Pharmaceuticals, Inc. ($ASPX) and 10% Owner in Neos Therapeutics, Inc. ($NEOS) and 10% Owner in Schrodinger, Inc. ($SDGR) and 10% Owner in CytomX Therapeutics, Inc. ($CTMX) and Director in Acutus Medical, Inc. ($AFIB) and 10% Owner in Annexon, Inc. ($ANNX) and 10% Owner in Aclaris Therapeutics, Inc. ($ACRS) and 10% Owner in Syros Pharmaceuticals, Inc. ($SYRS) and 10% Owner in Mallinckrodt plc ($MNK) and 10% Owner in Loxo Oncology, Inc. ($LOXO) and 10% Owner in Adverum Biotechnologies, Inc. ($AAVL) and 10% Owner in REGENXBIO Inc. ($RGNX) and 10% Owner in Recro Pharma, Inc. ($REPH) and 10% Owner in Nivalis Therapeutics, Inc. ($NVLS) and Director in Nivalis Therapeutics, Inc. ($NVLS) and 10% Owner in Audentes Therapeutics, Inc. ($BOLD) and 10% Owner in SteadyMed Ltd. ($STDY) and 10% Owner in ShockWave Medical, Inc. ($SWAV) and 10% Owner in RHYTHM PHARMACEUTICALS, INC. ($RYTM) and 10% Owner in Editas Medicine, Inc. ($EDIT) and Director in AveXis, Inc. ($AVXS) and 10% Owner in ARVINAS INC. ($ARVN) and 10% Owner in Homology Medicines, Inc. ($FIXX) and Director in Homology Medicines, Inc. ($FIXX) and Director in Oncorus, Inc. ($ONCR) and 10% Owner in Revolution Medicines, Inc. ($RVMD) and 10% Owner in Black Diamond Therapeutics, Inc. ($BDTX) and 10% Owner in Frequency Therapeutics, Inc. ($FREQ) and Director in DFB Healthcare Acquisitions Corp. ($DFBH) and 10% Owner in Generation Bio Co. ($GBIO) and 10% Owner in Kiniksa Pharmaceuticals, Ltd. ($KNSA) and 10% Owner in Mirum Pharmaceuticals, Inc. ($MIRM) and 10% Owner in Cabaletta Bio, Inc. ($CABA) and 10% Owner in Werewolf Therapeutics, Inc. ($HOWL) and 10% Owner in Nkarta, Inc. ($NKTX) and 10% Owner in Edgewise Therapeutics, Inc. ($EWTX) and Director in DFP HEALTHCARE ACQUISITIONS CORP. ($DFPH) and Director in Deerfield Healthcare Technology Acquisitions Corp. ($DFHT) and 10% Owner in Terns Pharmaceuticals, Inc. ($TERN).
James E Flynn in ALIMERA SCIENCES INC
Trading Symbol: ALIMIndustry: PHARMACEUTICAL PREPARATIONS [2834]
Position of James E Flynn: 10% Owner
Holdings: 728,718 shares
Current Value: $845,313
Latest Transaction: Dec 08 2015
$ALIM Market Capitalization: $75.24M
$ALIM Previous Close: $1.16
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of James E Flynn in ALIMERA SCIENCES INC
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ACRS, AFIB, DFBH, ADVM, ALIM, ALPN, ANNX, ATRS, ARNA, ARVN, LIFE, BOLD, ASPX, AVDL, AVXS, LECT, BDTX, CABA, CAMY.OB, CBIO, CNST, CYCC, CTMX, DFHTW, DFPHU, DRNA, DUSA, DVAX, EWTX, EDIT, EHTH, EMAG, FCSC, FREQ, GBIO, HITK, FIXX, ISPH, IVTY, ISTA, KNSA, LRMR, LOXO, NLNK, MNK, MDCO, MIRM, NEOS, NGSX, NURO, NTMD, NKTX, NXTM, ONCR, PRX, TARA, REPH, RGNX, RVMD, RYTM, RIGL, SDGR, SWAV, STDY, LANV, SYRS, EMLR, TERN, TWTI, TRIV, VNDA, CAQ, HOWL, XNPT, XERS
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Dec 08 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 3.04 | 27,530 | 83,774 | 728,718 | 701.2 K to 728.7 K (+3.93 %) |
Dec 08 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 3.04 | 27,529 | 83,771 | 4,760,408 | 4.7 M to 4.8 M (+0.58 %) |
Dec 08 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 3.00 | 68,294 | 204,848 | 701,188 | 632.9 K to 701.2 K (+10.79 %) |
Dec 08 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 3.00 | 68,294 | 204,848 | 4,732,879 | 4.7 M to 4.7 M (+1.46 %) |
Dec 08 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 3.01 | 40,301 | 121,169 | 632,894 | 592.6 K to 632.9 K (+6.80 %) |
Dec 08 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 3.01 | 40,301 | 121,169 | 4,664,585 | 4.6 M to 4.7 M (+0.87 %) |
Dec 03 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 3.00 | 53,487 | 160,589 | 592,593 | 539.1 K to 592.6 K (+9.92 %) |
Dec 03 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 3.00 | 53,486 | 160,586 | 4,624,284 | 4.6 M to 4.6 M (+1.17 %) |
Dec 03 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 2.98 | 55,257 | 164,876 | 539,106 | 483.8 K to 539.1 K (+11.42 %) |
Dec 03 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 2.98 | 55,257 | 164,876 | 4,570,798 | 4.5 M to 4.6 M (+1.22 %) |
Dec 03 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 3.05 | 12,882 | 39,273 | 483,849 | 471 K to 483.8 K (+2.74 %) |
Dec 03 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 3.05 | 12,883 | 39,276 | 4,515,541 | 4.5 M to 4.5 M (+0.29 %) |
Nov 10 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 2.98 | 36,625 | 109,241 | 470,967 | 434.3 K to 471 K (+8.43 %) |
Nov 10 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 2.98 | 36,625 | 109,241 | 4,502,658 | 4.5 M to 4.5 M (+0.82 %) |
Nov 03 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 3.00 | 8,271 | 24,813 | 434,342 | 426.1 K to 434.3 K (+1.94 %) |
Nov 03 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 3.00 | 8,271 | 24,813 | 4,466,033 | 4.5 M to 4.5 M (+0.19 %) |
Oct 29 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 2.99 | 13,165 | 39,363 | 426,071 | 412.9 K to 426.1 K (+3.19 %) |
Oct 29 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 2.99 | 13,165 | 39,363 | 4,457,762 | 4.4 M to 4.5 M (+0.30 %) |
Oct 29 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 3.00 | 16,506 | 49,518 | 412,906 | 396.4 K to 412.9 K (+4.16 %) |
Oct 29 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 3.00 | 16,506 | 49,518 | 4,444,597 | 4.4 M to 4.4 M (+0.37 %) |
Oct 26 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 3.00 | 17,117 | 51,361 | 396,400 | 379.3 K to 396.4 K (+4.51 %) |
Oct 26 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 3.00 | 17,116 | 51,358 | 4,428,091 | 4.4 M to 4.4 M (+0.39 %) |
Oct 26 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 3.00 | 12,090 | 36,270 | 379,283 | 367.2 K to 379.3 K (+3.29 %) |
Oct 26 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 3.00 | 12,091 | 36,273 | 4,410,975 | 4.4 M to 4.4 M (+0.27 %) |
Oct 26 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 3.00 | 975 | 2,925 | 367,193 | 366.2 K to 367.2 K (+0.27 %) |
Oct 26 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 3.00 | 975 | 2,925 | 4,398,884 | 4.4 M to 4.4 M (+0.02 %) |
Oct 21 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 3.00 | 80,342 | 241,042 | 366,218 | 285.9 K to 366.2 K (+28.10 %) |
Oct 21 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 3.00 | 80,342 | 241,042 | 4,397,909 | 4.3 M to 4.4 M (+1.86 %) |
Oct 21 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 3.00 | 50,065 | 150,060 | 285,876 | 235.8 K to 285.9 K (+21.23 %) |
Oct 21 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 3.00 | 50,065 | 150,060 | 4,317,567 | 4.3 M to 4.3 M (+1.17 %) |
Oct 21 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 2.92 | 64,613 | 188,825 | 235,811 | 171.2 K to 235.8 K (+37.74 %) |
Oct 21 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 2.92 | 64,613 | 188,825 | 4,267,502 | 4.2 M to 4.3 M (+1.54 %) |
Oct 09 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 2.53 | 71,540 | 180,710 | 171,198 | 99.7 K to 171.2 K (+71.79 %) |
Oct 09 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 2.53 | 71,540 | 180,710 | 4,202,889 | 4.1 M to 4.2 M (+1.73 %) |
Oct 09 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 2.50 | 19,817 | 49,543 | 99,658 | 79.8 K to 99.7 K (+24.82 %) |
Oct 09 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 2.50 | 19,816 | 49,540 | 4,131,349 | 4.1 M to 4.1 M (+0.48 %) |
Oct 09 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 2.30 | 69,536 | 159,724 | 79,841 | 10.3 K to 79.8 K (+674.78 %) |
Oct 09 2015 | ALIM | ALIMERA SCIENCES I ... | Flynn James E | 10% Owner | Buy | P | 2.30 | 69,536 | 159,724 | 4,111,533 | 4 M to 4.1 M (+1.72 %) |
Page: 1